This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Invest in Align Technology (ALGN) Now
by Zacks Equity Research
Align Technology (ALGN) continues to boost investors' confidence on consistent strength in InvisAlign.
PetMed (PETS) Down 7.8% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
PetMed (PETS) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
AmerisourceBergen to Take Over H. D. Smith for $815 Million
by Zacks Equity Research
AmerisourceBergen (ABC) strives to strengthen core businesses. The H. D. Smith buyout is likely to strengthen the Pharmaceutical Distribution Segment.
DexCom-Lily Partnership to Boost CGM Platform, Customer Base
by Zacks Equity Research
DexCom (DXCM) continues to sign deals to boost CGM platform adoption.
Here's Why You Should Offload Fresenius Medical Stock Now
by Zacks Equity Research
Fresenius (FMS) grapples with multiple issues. An unfavorable estimate revision trend adds to the woes.
Varian to Open Facility in Brazil, Global Growth in Focus
by Zacks Equity Research
Varian's (VAR) strong overseas presence is likely to fortify its foothold in the emerging markets. The recent initiative would boost its presence in Latin America.
Rising Costs Hurt Henry Schein, End-Market Trends a Tailwind
by Zacks Equity Research
Higher cost of sales and expenses hurt Henry Schein's (HSIC) gross and operating margin. However, several end market trends like demographics are likely to benefit the company.
5 Cheap Dividend Growth Stocks for Thanksgiving
by Sweta Killa
Stuff dividend stocks with strong growth prospects in your portfolio for market-beating returns this Thanksgiving Day.
Medtronic (MDT) Beats on Q2 Earnings, Reiterates FY18 View
by Zacks Equity Research
Medtronic (MDT) rides high on strength in major business segments in Q2.
Patterson Companies (PDCO) Misses on Q2 Earnings, Cuts View
by Zacks Equity Research
Patterson Companies (PDCO) missed estimates for both the counts in Q2. A downbeat guidance indicates looming concerns.
Medtronic Wins FDA Nod for Azure Pacemakers, Grows in CVG
by Zacks Equity Research
Medtronic (MDT) strives to improve its Cardiac Rhythm and Heart Failure division.
DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) renewed distribution deal will help the company gain market traction. However, forex woes remain a concern.
McKesson Gains From Distribution Business Amid Pricing Woes
by Zacks Equity Research
McKesson Corporation's (MCK) Distribution business is driven by market growth and acquisitions. However, pricing remains a concern.
Haemonetics (HAE) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Haemonetics (HAE) focuses on development and launch of NexSys PCS plasmapheresis system.
Varian's Halcyon Receives Shonin Approval, Grows in Oncology
by Zacks Equity Research
Varian Medical (VAR) adopts various strategies to boost the Oncology Segment.
AmerisourceBergen's PharMEDium Slows Down, Competition Rife
by Zacks Equity Research
AmerisourceBergen's (ABC) prospects hurt by tepid performance at PharMEDium. Also, steep competition is a cause for concern.
Align Technology-Glidewell Dental Deal to Boost iTero Uptake
by Zacks Equity Research
Align Technology (ALGN) progresses with deals to boost the Scanners and Services segment.
Intuitive Surgical Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
The market is upbeat about Intuitive Surgical's (ISRG) solid procedure performance in Asia, with growth in China, Japan and Korea.
Wright Medical (WMGI) Rides on Strong Portfolio & Innovation
by Zacks Equity Research
Wright Medical (WMGI) is focused on product innovation through research and development. However, lackluster international performance of the lower extremities segment is a matter of concern.
Genomic Health Cancer Diagnostic Tests Grow Amid Cost Woes
by Zacks Equity Research
Revenues at Genomic Health (GHDX) improve year over year in Q3, driven by solid performances in the United States and internationally. However, rising operating losses continue to be a spoiler.
Medtronic Stock Dips on Preliminary Sales Drag, CRHF to Grow
by Zacks Equity Research
Medtronic's (MDT) latest preliminary sales update for the second quarter of fiscal 2018 holds the market in a bleak light.
Ecolab (ECL) to Refinance $375M Worth of Notes, Reduce Debt
by Zacks Equity Research
Ecolab (ECL) plans to reduce debt by refinancing notes with a lower coupon rate.
Luminex (LMNX) Banks on FDA Approvals & Portfolio Strength
by Zacks Equity Research
Luminex's (LMNX) collaborative agreements with several companies should help expand the adoption of its products.
Intuitive Surgical (ISRG) to Gain From Procedural Business
by Zacks Equity Research
Intuitive Surgical's (ISRG) sales to gain from on da Vinci system and procedural growth in general surgery, oncology, urology and gynecology.
LabCorp Reports New Use of Agilent's Cancer Diagnostic Test
by Zacks Equity Research
The testing of the clinical studies needed to approve PD-L1 IHC 28-8 pharmDx assay's new indications were performed at LabCorp's (LH) Center for Molecular Biology and Pathology laboratory.